Cadence Bank’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $12.6M | Buy |
232,856
+3,655
| +2% | +$176K | 0.74% | 28 |
|
|
2025
Q3 | $10.3M | Buy |
229,201
+50,628
| +28% | +$2.36M | 0.63% | 33 |
|
|
2025
Q2 | $8.27M | Buy |
178,573
+5,457
| +3% | +$268K | 0.54% | 40 |
|
|
2025
Q1 | $10.6M | Buy |
173,116
+3,558
| +2% | +$207K | 0.75% | 27 |
|
|
2024
Q4 | $9.59M | Sell |
169,558
-2,241
| -1% | -$125K | 0.65% | 31 |
|
|
2024
Q3 | $8.89M | Buy |
171,799
+2,681
| +2% | +$126K | 0.61% | 36 |
|
|
2024
Q2 | $7.02M | Buy |
169,118
+3,959
| +2% | +$177K | 0.53% | 41 |
|
|
2024
Q1 | $8.96M | Buy |
165,159
+290
| +0.2% | +$14.8K | 0.65% | 35 |
|
|
2023
Q4 | $8.46M | Buy |
164,869
+45,053
| +38% | +$2.36M | 0.69% | 33 |
|
|
2023
Q3 | $6.95M | Buy |
119,816
+1,234
| +1% | +$75.6K | 0.61% | 37 |
|
|
2023
Q2 | $7.58M | Buy |
118,582
+910
| +0.8% | +$61K | 0.66% | 34 |
|
|
2023
Q1 | $8.16M | Buy |
117,672
+647
| +0.6% | +$45.6K | 0.75% | 28 |
|
|
2022
Q4 | $8.42M | Buy |
117,025
+1,978
| +2% | +$149K | 0.78% | 28 |
|
|
2022
Q3 | $8.18M | Buy |
115,047
+8,538
| +8% | +$619K | 0.85% | 25 |
|
|
2022
Q2 | $8.2M | Sell |
106,509
-2,316
| -2% | -$176K | 1.18% | 23 |
|
|
2022
Q1 | $7.95M | Buy |
108,825
+601
| +0.6% | +$40.4K | 0.99% | 29 |
|
|
2021
Q4 | $6.75M | Buy |
108,224
+2,943
| +3% | +$173K | 0.84% | 33 |
|
|
2021
Q3 | $6.23M | Buy |
105,281
+2,841
| +3% | +$187K | 0.87% | 35 |
|
|
2021
Q2 | $6.84M | Sell |
102,440
-7,423
| -7% | -$484K | 0.99% | 28 |
|
|
2021
Q1 | $6.93M | Buy |
109,863
+3,015
| +3% | +$188K | 1.05% | 26 |
|
|
2020
Q4 | $6.63M | Buy |
106,848
+10,684
| +11% | +$657K | 1.04% | 25 |
|
|
2020
Q3 | $5.8M | Buy |
96,164
+5,074
| +6% | +$305K | 1.14% | 22 |
|
|
2020
Q2 | $5.36M | Buy |
91,090
+34
| +0% | +$2.03K | 1.11% | 22 |
|
|
2020
Q1 | $5.08M | Buy |
91,056
+2,177
| +2% | +$133K | 1.28% | 19 |
|
|
2019
Q4 | $5.71M | Buy |
88,879
+215
| +0.2% | +$12.3K | 1.05% | 21 |
|
|
2019
Q3 | $4.5M | Buy |
88,664
+2,476
| +3% | +$116K | 0.42% | 38 |
|
|
2019
Q2 | $3.91M | Buy |
86,188
+31,200
| +57% | +$1.45M | 0.38% | 47 |
|
|
2019
Q1 | $2.62M | Buy |
54,988
+48
| +0.1% | +$2.39K | 0.26% | 61 |
|
|
2018
Q4 | $2.86M | Buy |
54,940
+48,863
| +804% | +$2.63M | 0.34% | 54 |
|
|
2018
Q3 | $377K | Sell |
6,077
-953
| -14% | -$56.6K | 0.04% | 180 |
|
|
2018
Q2 | $389K | Hold |
7,030
| – | – | 0.04% | 176 |
|
|
2018
Q1 | $445K | Sell |
7,030
-112
| -2% | -$7.21K | 0.04% | 155 |
|
|
2017
Q4 | $438K | Buy |
+7,142
| New | +$447K | 0.04% | 164 |
|
Other funds holding BMY
Cadence Bank's BMY Position: Q4 2025 in Review
Cadence Bank increased its Bristol-Myers Squibb (BMY) stake by 1.6% in Q4 2025, buying an estimated $176K and bringing the position to 232,856 shares worth $12.6M. The position accounts for 0.74% of the portfolio, ranked #28.
Cadence Bank first reported a position in BMY in Q4 2017 and has held it in 33 quarters since. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.
- Cadence Bank held 232,856 shares of Bristol-Myers Squibb worth $12.6M as of Q4 2025.
- Cadence Bank bought 3,655 Bristol-Myers Squibb shares in Q4 2025, an estimated $176K.
- Bristol-Myers Squibb made up 0.74% of Cadence Bank's portfolio in Q4 2025, its #28 holding.
- Cadence Bank first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 33 quarters since.
- 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.
Based on Cadence Bank's 13F filing for Q4 2025, filed 30 Jan 2026.